Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - gadopentetate dimeglumine, quantity: 469.01 mg/ml - injection, solution - excipient ingredients: water for injections; meglumine; pentetate meglumine - indications as at 30 august 1996: using magnetic resonance imaging (mri) dimeglumine gadopentetate provides contrast enhancement; in intracranial and spinal lesions in adults and children, including neonates and infants, with an abnormal blood-brain barrier, or abnormal vascularity; in whole body imaging in adult patients , including the neck region, the thoracic and abdominal space, the female breast, the pelvis and the musculoskeletal system. note: reliable enhancement is not provided in imaging the pancreas and the male reproductive organs (prostate, testis and penis).

Australia - English - Department of Health (Therapeutic Goods Administration)

boc limited - oxygen, quantity: 100 % v/v - gas, medicinal - excipient ingredients: - for respiratory delivery where there is a requirement for medical oxygen to treat or prevent hypoxemia

Australia - English - Department of Health (Therapeutic Goods Administration)

air liquide healthcare pty ltd - nitrous oxide, quantity: 0.5 l/l; oxygen, quantity: 0.5 l/l - gas, medicinal - excipient ingredients: - indications as at 31 october 2001: nitrous oxide with oxygen (nitronox) is indicated in adults and children for analgesia.

Israel - English - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - posaconazole - gastro resistant tablets - posaconazole 100 mg - posaconazole - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults:- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.- zygomycosis in patients intolerant of or with disease that is refractory to alternative therapy.refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lupin healthcare (uk) ltd - valproate semisodium - gastro-resistant tablet - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

lupin healthcare (uk) ltd - valproate semisodium - gastro-resistant tablet - 250mg

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - gadolinium oxide; dota acid; meglumine; gadoteric acid - solution for injection - 279.32 milligram(s)/millilitre - paramagnetic contrast media; gadoteric acid

Ireland - English - HPRA (Health Products Regulatory Authority)

bayer limited - gadolinium oxide; dota acid; meglumine - solution for injection - 279.32 milligram(s)/millilitre - paramagnetic contrast media; gadoteric acid

Australia - English - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - amidotrizoate meglumine, quantity: 660 mg/ml; sodium amidotrizoate, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: disodium edetate; anise oil; polysorbate 80; saccharin; purified water - gastrografin is a contrast medium for examination of the gastrointestinal tract. it can be administered orally and as enema and is primarily indicated in cases in which the use barium sulfate is unsatisfactory, undesirable or contraindicated. among these are: - suspected partial or complete stenosis - acute haemorrhage - threatening perforation (peptic ulcer, diverticulum) - other acute conditions which are likely to require surgery - after resection of the stomach or the intestine (danger of perforation or leak) - megacolon - visualisation of a foreign body or tumour before endoscopy - visualisation of gastrointestinal fistula. in addition to these conditions gastrografin can generally be used for the same purposes as barium sulfate with the exception of the visualisation of mucosal diseases. due to the insufficient coating properties of gastrografin, barium sulfate should be used for single or double contrast techniques. in combination with barium sulfate, gastrografin has considerably improved routine inve

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - gabapentin, quantity: 600 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; copovidone; poloxamer; maize starch; purified talc - gapentin is indicated for the treatment of partial seizures, including secondarily generalised tonic-clonic seizures, initially as add-on therapy in adults who have not achieved adequate control with standard antiepileptic drugs. gapentin is indicated for the treatment of neuropathic pain.